Merck & Co. (MRK) : Lincluden Management Ltd scooped up 4,115 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 34,155 shares of Merck & Co. which is valued at $1,937,955.Merck & Co. makes up approximately 0.31% of Lincluden Management Ltd’s portfolio.
Merck & Co. opened for trading at $56.06 and hit $56.62 on the upside on Wednesday, eventually ending the session at $56.31, with a gain of 0.48% or 0.27 points. The heightened volatility saw the trading volume jump to 69,41,426 shares. Company has a market cap of $156,275 M.
Other Hedge Funds, Including , Headinvest boosted its stake in MRK in the latest quarter, The investment management firm added 1,575 additional shares and now holds a total of 26,045 shares of Merck & Co. which is valued at $1,477,793. Merck & Co. makes up approx 0.57% of Headinvest’s portfolio. Exencial Wealth Advisors sold out all of its stake in MRK during the most recent quarter. The investment firm sold 24,525 shares of MRK which is valued $1,391,549.Jacobs Coca boosted its stake in MRK in the latest quarter, The investment management firm added 13 additional shares and now holds a total of 46,680 shares of Merck & Co. which is valued at $2,620,615. Merck & Co. makes up approx 0.62% of Jacobs Coca’s portfolio.Lgt Capital Partners Ltd. boosted its stake in MRK in the latest quarter, The investment management firm added 156,590 additional shares and now holds a total of 519,300 shares of Merck & Co. which is valued at $28,587,465. Merck & Co. makes up approx 5.17% of Lgt Capital Partners Ltd.’s portfolio.Iowa State Bank boosted its stake in MRK in the latest quarter, The investment management firm added 167 additional shares and now holds a total of 43,591 shares of Merck & Co. which is valued at $2,399,685. Merck & Co. makes up approx 1.36% of Iowa State Bank’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.